• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Medin Technologies, Inc. Completes Add-on Acquisition of Advantage Manufacturing Technologies, Inc., Expands Platform in Medical Manufacturing

Share:

July 8, 2019

Medin Technologies, Inc., a medical contract manufacturer owned by Seven Point Equity Partners LLC and headquartered in Totowa, New Jersey, announced its completed add-on acquisition of Monroe, Washington-based Advantage Manufacturing Technologies, Inc., a manufacturer of orthopedic implants, through a newly formed, wholly owned subsidiary named AMT Medical, Inc.

AMT Medical will continue AMT’s proud tradition of customer-focused leadership in orthopedic implant manufacturing. In combination with Medin Technologies, AMT Medical benefits from an augmented management team, a broadened product offering and greater financial resources. David Parsons, the former owner of AMT, has retained a minority ownership position in the company and will serve on the executive team. Seven Point Operating Partner Stephen Goddard has been appointed as the CEO of AMT Medical, reporting to Bill Donaldson, CEO of Medin Technologies.

“We are excited to have completed this important add-on acquisition,” stated Bill Donaldson, Medin Technologies’ CEO. “Medin’s strategic goal is to provide world-class quality and performance across multiple product and component lines as a full-service manufacturing partner to our orthopedic OEM customers. Together, with AMT Medical, we can execute that strategy on a more comprehensive scale. Just as we have done with Medin Technologies, we plan to invest aggressively in AMT Medical, and over time, integrate the two companies’ operations more thoroughly to deliver value to our customers.”

Tom Burchill, Seven Point Equity Partners’ Managing Partner, added, “Acquiring AMT strengthens Medin Technologies’ business model and offers compelling, immediate and long-term operational and strategic value. In addition to participating in two attractive markets in cases and trays and orthopedic implants, the combined companies serve a diverse set of high growth end markets in trauma, extremity, spine, knee and hips. We provided 100% of the capital required for the acquisition as equity capital, reflecting our desire to give the management team maximum flexibility to invest in the business and grow aggressively.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Seven Point Partner and Medin board member Mark Kammert added, “This additional investment in Medin Technologies highlights our strategy of acquiring businesses with complex capital and operational needs and transforming them with talented operating partners, in this case, with the Medin management team led by CEO Bill Donaldson and AMT Medical CEO Stephen Goddard. AMT Medical is our second investment in the medical manufacturing sector and demonstrates our commitment to the industry.”

Medin did not use outside lenders to complete the transaction. Benesch, Friedlander, Coplan & Aronoff LLP acted as legal advisor to Seven Point and Medin Technologies in this transaction. The Tracy Law Group acted as AMT’s legal advisor, and Kinsella Group served as its financial advisor.

Date: July 08, 2019

Source: Yahoo Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • PeerWell Announces $6.5 Million in Series A Funding to Rollout Musculoskeletal Surgery Optimization PlatformPeerWell Announces $6.5 Million in Series A Funding to Rollout Musculoskeletal Surgery Optimization Platform
  • Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analystJohnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst
  • NTT Data Services to Acquire NETE, Expanding Digital Transformation Capabilities in the Federal Healthcare SectorNTT Data Services to Acquire NETE, Expanding Digital Transformation Capabilities in the Federal Healthcare Sector
  • ApolloMD Partners with Cedar to Implement Optimized Online Patient Billing ExperienceApolloMD Partners with Cedar to Implement Optimized Online Patient Billing Experience
  • OncoCyte (OCX) to Acquire Insight GeneticsOncoCyte (OCX) to Acquire Insight Genetics
  • Clinicians, developers must address these 3 concerns before using AI-enabled diagnostic supportClinicians, developers must address these 3 concerns before using AI-enabled diagnostic support
  • Bruker extends microscopy offering with JPK acquisitionBruker extends microscopy offering with JPK acquisition
  • How Intelligent Automation Can Address 3 Revenue Cycle ChallengesHow Intelligent Automation Can Address 3 Revenue Cycle Challenges

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications